


CLAIMS

1. A composition comprising a salt of a compound represented by Formula (I):



wherein:

R^1 , R^2 , and R^3 are each independently H or substituted or unsubstituted alkyl, alkoxy, haloalkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, heteroalkyl, cycloalkyl, heterocyclyl, or heterocyclalkyl;

R^4 , independently for each occurrence, is selected from substituted or unsubstituted alkyl, aryl, arylalkyl, heterocyclyl, oxo, $-OR^b$, $-CH_2OR^b$, halo, hydroxyl, and hydroxyalkyl;


R^b is substituted or unsubstituted alkyl, aryl, arylalkyl, or heterocyclyl;

p is 0, 1, or 2;

R^6 is hydrogen or substituted or unsubstituted alkyl; and

R^7 , R^8 , and R^9 are each independently hydrogen or alkyl;

wherein the compound is not:



wherein at least 90% of the compound in the composition is present as the salt.

2. The composition of claim 1, wherein:

R^1 , R^2 , and R^3 are each independently H or substituted or unsubstituted alkyl, arylalkyl, or heterocyclalkyl;

R^4 , independently for each occurrence, is selected from substituted or unsubstituted alkyl, oxo, hydroxyl, $-OR^b$, hydroxyalkyl, $-CH_2OR^b$, and halo;

R^b is substituted or unsubstituted alkyl, aryl, arylalkyl, or heterocyclyl;

R^6 is hydrogen or substituted or unsubstituted alkyl; and

R^7 , R^8 , and R^9 are each independently hydrogen or alkyl.

3. The composition of claim 1 or 2, wherein, where indicated, alkyl, alkoxy, haloalkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, heteroalkyl, cycloalkyl, heterocyclyl, or heterocyclalkyl is unsubstituted or is substituted with one or more substituents selected from halo, haloalkyl, oxo, -CN, -NO₂, =N-OH, -N₃, -R^a, -OR^a, -SR^a, -N(R^a)₂, -N(R^a)₃⁺, =NR^a, -NHC(=O)R^c, -C(=O)R^c, -C(=O)N(R^a)₂, -S(=O)₂R^c, -OS(=O)₂OR^a, -S(=O)₂OR^a, -S(=O)₂N(R^a)₂, -S(=O)R^c, -OP(=O)(OR^a)₂, -(alkylene)-C(=O)R^c, -C(=S)R^c, -C(=O)OR^a, -(alkylene)-C(=O)OR^a, -C(=S)OR^a, -C(=O)SR^a, -C(=S)SR^a, -(alkylene)-C(=O)N(R^a)₂, -C(=S)N(R^a)₂, and -C(-NR^a)N(R^a)₂;

R^a, independently for each occurrence, is hydrogen, or substituted or unsubstituted alkyl, aryl, arylalkyl, heterocyclyl, heterocyclalkyl, cycloalkyl, or cycloalkylalkyl; and


R^c, independently for each occurrence, is substituted or unsubstituted alkyl, aryl, arylalkyl, heterocyclyl, heterocyclalkyl, cycloalkyl, or cycloalkylalkyl.



4. The composition of any one of claims 1-3, wherein, where indicated, alkyl, alkoxy, haloalkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, heteroalkyl, cycloalkyl, heterocyclyl, or heterocyclalkyl is unsubstituted or is substituted with one or more substituents selected from halo, haloalkyl, oxo, -R^a, -OR^a, -N(R^a)₂, -N(R^a)₃⁺, -NHC(=O)R^c, -C(=O)R^c, -C(=O)N(R^a)₂, -C(=O)OR^a, -(alkylene)-C(=O)OR^a, and -(alkylene)-C(=O)N(R^a)₂;

R^a, independently for each occurrence, is hydrogen, or substituted or unsubstituted alkyl, aryl, arylalkyl, heterocyclyl, heterocyclalkyl, cycloalkyl, or cycloalkylalkyl; and


R^c, independently for each occurrence, is substituted or unsubstituted alkyl, aryl, arylalkyl, heterocyclyl, heterocyclalkyl, cycloalkyl, or cycloalkylalkyl.

5. The composition of any one of claims 1-4, wherein R¹ is selected from






R^3 is selected from



p is 1 or 2; and R^4 , independently for each occurrence, is selected from $-CH_3$, halo, hydroxyl, hydroxyalkyl, and oxo; and/or



R^7 is (C_1-C_{10}) alkyl; and/or





R^8 is $-CH_3$ or $-H$; and/or






R^9 is $-CH_3$ or $-H$.






6. The composition of any one of claims 1-5, wherein the compound comprises at least one D-amino acid residue.

7. The composition of any one of claims 1-6, wherein the compound comprises at least two, at least three, at least four, at least five, at least six, at least seven, or at least eight D-amino acid residues.


8. The composition of claim 1, wherein the compound is selected from the following:


















, and







9. The composition of claim 1, wherein the compound is selected from the following:





























10. The composition of claim 1, wherein the compound is selected from the following:













11. The composition of claim 1, wherein the compound is selected from the following:






12. The composition of claim 1, wherein the compound is selected from the following:



13. A compound represented by Formula (I):



or a pharmaceutically acceptable salt thereof;

wherein:

R^1 , R^2 , and R^3 are each independently H or substituted or unsubstituted alkyl, alkoxy, haloalkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, heteroalkyl, cycloalkyl, heterocyclyl, or heterocyclalkyl;

R^4 , independently for each occurrence, is selected from substituted or unsubstituted alkyl, aryl, arylalkyl, heterocyclyl, oxo, $-OR^b$, $-CH_2OR^b$, halo, hydroxyl, and hydroxyalkyl;

R^b is substituted or unsubstituted alkyl, aryl, arylalkyl, or heterocyclyl;

p is 0, 1, or 2;

R^6 is hydrogen or substituted or unsubstituted alkyl; and

R^7 , R^8 , and R^9 are each independently hydrogen or alkyl;

wherein at least one of:

(a) at least one of R^1 , R^2 , and R^3 is substituted or unsubstituted (C_2-C_{10}) haloalkyl;

(b) at least one of alkyl, alkoxy, haloalkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, heteroalkyl, cycloalkyl, heterocyclyl, or heterocyclalkyl is substituted with one or more substituents selected from $-R^a$, $-OR^a$, $-SR^a$, $-N(R^a)_2$, $-N(R^a)_3^+$, $=NR^a$, $-NHC(=O)R^c$, $-C(=O)R^c$, $-C(=O)N(R^a)_2$, $-S(=O)_2R^c$, $-OS(=O)_2OR^a$, $-S(=O)_2OR^a$, $-S(=O)_2N(R^a)_2$, $-S(=O)R^c$, $-OP(=O)(OR^a)_2$, $-(alkylene)-C(=O)R^c$, $-C(=S)R^c$, $-C(=O)OR^a$, $-(alkylene)-C(=O)OR^a$, $-C(=S)OR^a$, $-C(=O)SR^a$, $-C(=S)SR^a$, $-(alkylene)-C(=O)N(R^a)_2$, $-C(=S)N(R^a)_2$, and $-C(-NR^a)N(R^a)_2$; and

R^a and R^c are each independently heterocyclalkyl, cycloalkyl, or cycloalkylalkyl;

(c) the compound comprises at least one D-amino acid residue; or




(d) at least two occurrences of R^a ;




at least two occurrences of R^c ; or

at least one occurrence of R^a and at least one occurrence of R^c ; and

at least one occurrence of R^a and/or R^c differs from the other occurrences; and

wherein the compound is not:





14. The compound of claim 13, wherein at least one of R^1 , R^2 , and R^3 is substituted or unsubstituted (C_2 - C_{10})haloalkyl.

15. The compound of claim 13 or 14, wherein at least one of alkyl, alkoxy, haloalkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, heteroalkyl, cycloalkyl, heterocyclyl, or heterocyclylalkyl is substituted with one or more substituents selected from $-R^a$, $-OR^a$, $-SR^a$, $-N(R^a)_2$, $-N(R^a)_3^+$, $=NR^a$, $-NHC(=O)R^c$, $-C(=O)R^c$, $-C(=O)N(R^a)_2$, $-S(=O)_2R^c$, $-OS(=O)_2OR^a$, $-S(=O)_2OR^a$, $-S(=O)_2N(R^a)_2$, $-S(=O)R^c$, $-OP(=O)(OR^a)_2$, $-(alkylene)-C(=O)R^c$, $-C(=S)R^c$, $-C(=O)OR^a$, $-(alkylene)-C(=O)OR^a$, $-C(=S)OR^a$, $-C(=O)SR^a$, $-C(=S)SR^a$, $-(alkylene)-C(=O)N(R^a)_2$, $-C(=S)N(R^a)_2$, and $-C(-NR^a)N(R^a)_2$; and R^a and R^c are each independently heterocyclylalkyl, cycloalkyl, or cycloalkylalkyl.

16. The compound of any one of claims 13-15, wherein:

R^1 , R^2 , and R^3 are each independently H or substituted or unsubstituted alkyl, arylalkyl, or heterocyclalkyl;

R^4 , independently for each occurrence, is selected from substituted or unsubstituted alkyl, oxo, hydroxyl, $-OR^b$, hydroxyalkyl, $-CH_2OR^b$, and halo;

R^b is substituted or unsubstituted alkyl, aryl, arylalkyl, or heterocyclalkyl;

R^6 is hydrogen or substituted or unsubstituted alkyl; and

R^7 , R^8 , and R^9 are each independently hydrogen or alkyl.

17. The compound of any one of claims 13-16, wherein, where indicated, alkyl, alkoxy, haloalkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, heteroalkyl, cycloalkyl, heterocyclalkyl, or heterocyclalkyl is unsubstituted or is substituted with one or more substituents selected from halo, haloalkyl, oxo, $-CN$, $-NO_2$, $=N-OH$, $-N_3$, $-R^a$, $-OR^a$, $-SR^a$, $-N(R^a)_2$, $-N(R^a)_3^+$, $=NR^a$, $-NHC(=O)R^c$, $-C(=O)R^c$, $-C(=O)N(R^a)_2$, $-S(=O)_2R^c$, $-OS(=O)_2OR^a$, $-S(=O)_2OR^a$, $-S(=O)_2N(R^a)_2$, $-S(=O)R^c$, $-OP(=O)(OR^a)_2$, $-(alkylene)-C(=O)R^c$, $-C(=S)R^c$, $-C(=O)OR^a$, $-(alkylene)-C(=O)OR^a$, $-C(=S)OR^a$, $-C(=O)SR^a$, $-C(=S)SR^a$, $-(alkylene)-C(=O)N(R^a)_2$, $-C(=S)N(R^a)_2$, and $-C(-NR^a)N(R^a)_2$; and




R^a , independently for each occurrence, is hydrogen, or substituted or unsubstituted alkyl, aryl, arylalkyl, heterocyclalkyl, heterocyclalkyl, cycloalkyl, or cycloalkylalkyl; and

R^c , independently for each occurrence, is substituted or unsubstituted alkyl, aryl, arylalkyl, heterocyclalkyl, heterocyclalkyl, cycloalkyl, or cycloalkylalkyl.


18. The compound of any one of claims 13-17, wherein, where indicated, alkyl, alkoxy, haloalkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, heteroalkyl, cycloalkyl, heterocyclalkyl, or heterocyclalkyl is unsubstituted or is substituted with one or more substituents selected from halo, haloalkyl, oxo, $-R^a$, $-OR^a$, $-N(R^a)_2$, $-N(R^a)_3^+$, $-NHC(=O)R^c$, $-C(=O)R^c$, $-C(=O)N(R^a)_2$, $-C(=O)OR^a$, $-(alkylene)-C(=O)OR^a$, and $-(alkylene)-C(=O)N(R^a)_2$; and

R^a , independently for each occurrence, is hydrogen, or substituted or unsubstituted alkyl, aryl, arylalkyl, heterocyclalkyl, heterocyclalkyl, cycloalkyl, or cycloalkylalkyl; and


R^c , independently for each occurrence, is substituted or unsubstituted alkyl, aryl, arylalkyl, heterocyclalkyl, heterocyclalkyl, cycloalkyl, or cycloalkylalkyl.



and/or p is 1 or 2; and R⁴, independently for each occurrence, is selected from -CH₃, halo, hydroxyl, hydroxyalkyl, and oxo; and/or

R^6 is $-\text{CH}_3$ or ; and/or
 R^7 is $(\text{C}_1\text{-C}_{10})$ alkyl; and/or
 R^8 is $-\text{CH}_3$ or $-\text{H}$; and/or
 R^9 is $-\text{CH}_3$ or $-\text{H}$.

20. The compound of claim 13, wherein the compound is:



, or a pharmaceutically acceptable salt thereof.


21. The compound of claim 13, wherein the compound is a peptide having an amino acid sequence represented by HyP-Gly-Gln-Xaa-Gly-Leu-Ala-Gly-Pro-Lys;
 or a pharmaceutically acceptable salt and/or stereoisomer thereof;
 wherein Xaa is selected from Glu, Asn, Gln, His, Lys, Ser, Thr, Ala, Val, Ile, Leu, Phe, Tyr, Trp, homo-Ser, Asp(Me), and Asn(Me); and
 at least one amino acid residue in the peptide is a D-amino acid residue; or
 the compound is a peptide having an amino acid sequence represented by HyP-Gly-Gln-Asp-Xaa-Leu-Ala-Gly-Pro-Lys;
 or a pharmaceutically acceptable salt and/or stereoisomer thereof;
 wherein Xaa is selected from Val, Ile, Leu, Ala, Phe, Tyr, Trp, Ser, Thr, and (N-Me)Gly; and
 at least one amino acid residue in the peptide is a D-amino acid residue; or
 the compound is a peptide having an amino acid sequence represented by HyP-Gly-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Xaa;
 or a pharmaceutically acceptable salt and/or stereoisomer thereof;
 wherein Xaa is selected from Tyr, Leu, Glu, Gln, Ala, and Nle(6-OH); and

at least one amino acid residue in the peptide is a D-amino acid residue; or

the compound is a peptide having an amino acid sequence represented by Xaa-Gly-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Lys;

or a pharmaceutically acceptable salt and/or stereoisomer thereof;


wherein Xaa is selected from:



at least one amino acid residue in the peptide is a D-amino acid residue.


22. The compound of claim 21, wherein at least two, at least three, at least four, at least five, at least six, or at least seven amino acid residues in the peptide are D-amino acid residues.

23. A compound having the following structure:




; or a pharmaceutically acceptable salt thereof.

24. A composition comprising a salt of a compound represented by Formula 8:



[Formula 8]; or

represented by Formula 10:



[Formula 10]; and,







wherein at least 90% of the compound in the composition is present as the salt.







25. A pharmaceutical composition comprising a composition of claim 1 or 24 or a compound of any one of claims 13, 16-20, and 23 and a pharmaceutically acceptable carrier.




26. The pharmaceutical composition of claim 25, wherein the pharmaceutical composition is formulated for topical administration to the eye, e.g., as eye drops.

27. Use of a composition comprising a salt of a compound selected from the following table:

YDE-001	<p>Hyp (2S,4R) Gly Gln Glu Gly Leu Ala Gly Pro Lys</p>
---------	--

YDE-008	 <p>Hyp Gly Gln Ala Gly Leu Ala Gly Pro Lys NH₂</p> <p>(2<i>S</i>,4<i>R</i>)</p>
YDE-011	 <p>Hyp Gly Gln Leu Gly Leu Ala Gly Pro Lys NH₂</p> <p>(2<i>S</i>,4<i>R</i>)</p>
YDE-015	 <p>Hyp Gly Gln Asp Val Leu Ala Gly Pro Lys NH₂</p> <p>(2<i>S</i>,4<i>R</i>)</p>
YDE-016	 <p>Hyp Gly Gln Asp Ile Leu Ala Gly Pro Lys NH₂</p> <p>(2<i>S</i>,4<i>R</i>)</p>
YDE-023	 <p>Hyp Gly Gln Asp Ser Leu Ala Gly Pro Lys NH₂</p> <p>(2<i>S</i>,4<i>R</i>)</p>
YDE-026	 <p>Hyp Gly Gln Homo-Ser Gly Leu Ala Gly Pro Lys NH₂</p> <p>(2<i>S</i>,4<i>R</i>)</p>

YDE-038	 <p>(4-hydroxyMe)Pro Gly Gln Leu Gly Leu Ala Gly Pro Lys NH₂</p> <p>(2<i>S</i>,4<i>R</i>)</p>
YDE-044	 <p>(4-Me)Pro Gly Gln Leu Gly Leu Ala Gly Pro Lys NH₂</p>
YDE-045	 <p>(5-Me)Pro Gly Gln Leu Gly Leu Ala Gly Pro Lys NH₂</p>
YDE-048	 <p>Hyp Ala Gln Leu Gly Leu Ala Gly Pro Lys NH₂</p>
YDE-049	 <p>Hyp Gly Ala Leu Gly Leu Ala Gly Pro Lys NH₂</p>
YDE-054	 <p>Hyp Gly Gln Leu Gly Leu Ala Ala Pro Lys NH₂</p>

YDE-057	 <p>D-Hyp Gly Gln Leu Gly Leu Ala Gly Pro Lys (2R,4S)</p>
YDE-058	 <p>D-Hyp Gly D-Gln D-Leu Gly D-Leu D-Ala Gly D-Pro D-Lys (2R,4S)</p>
YDE-060	 <p>D-Hyp Gly D-Gln D-Leu Gly D-Leu D-Ala Gly D-Pro D-Lys (2R,4R)</p>

in the manufacture of a medicament for the treatment of an eye disease;
wherein at least 90% of the compound in the composition is present as the salt.

28. The use of claim 27, wherein the eye disease is selected from retinopathy, keratitis, dry-macular degeneration, wet-macular degeneration, dry eye syndrome, heratoconjunctivitis sicca and keratoconjunctival epithelium disorder.